| Prev Close | 225.59 |
| Day Low/High | 221.17 / 224.93 |
| 52 Wk Low/High | 166.30 / 244.99 |
| Avg Volume | 2.21M |
Amgen Inc. (AMGN)
222.95
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 594.18M |
| Market Cap | 134.04B |
| EPS | 12.70 |
| P/E Ratio | 17.33 |
| Div & Yield | 6.40 (2.47%) |
Latest News
3 Boomer-Inspired Drug Plays With Dividend Appeal
Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.
Amgen Gets Shot in the Arm, Could Bounce Up in Months Ahead
AMGN appears to have taken a turn for the better and is now looking at targets of $254 and $270.
RMPIA Lags in November, but Trounces S&P 500 for Quarter, Year So Far
Now, many Real Money Post Industrial Average stocks should see a boost from the holiday splurge by shoppers.
News While You Slept, Semi Tough and Updates on Amgen and Splunk: Market Recon
Also, Fed Chairman Powell says there are no plans for a U.S. digital currency (for now), plus Tesla's electric pickup.
Real Money Post Industrial Average Exits October on Top
The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.
Drug Companies Are a Political Football, Trading Amgen: Market Recon
The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.
We Prescribe Amgen to Treat Your Portfolio
According to the charts, the drugmaker should break out to new highs.
Jim Cramer: Drug Stocks Are Too Cheap
These stocks are priced for total imperfection. That's just what you want.
Sussing the Fed -- Plus Apple, Amgen and Other Earnings: Market Recon
Markets are watching what Fed Chair Powell will signal for future rate cuts during this afternoon's FOMC rate decision.
6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon
If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.
Jim Cramer: Demand Is Driving This Market to All-Time Highs
The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.
Arrowhead Pharmaceuticals Is Flying Higher on the Charts
Before I give my recommendation I want to visit with the charts and indicators.
Real Money Post-Industrial Average Continues to Outpace Major Indices
RMPIA is up 20.9% in the first nine months of 2019.
Jim Cramer: How to Survive This Violent Rotation
Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.
Could Small Drug Trial Hold Big Potential for Amgen?
The results of a lung-cancer drug got me to go long on the stock, but the larger picture is complicated.
Amgen's Lower Open Tests Support but the Bigger Picture Is More Important
Let's check out the charts to get a sense of where prices could be headed.
A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
Real Money Post-Industrial Average Holds Own in Turbulent August
Gains in Amgen, CVS, and others helped offset declines in other stocks, as the RMPIA rose over the last two months to 0.6%, handily beating all the major domestic stock market averages.
Otezla Price Under Microscope -- but Look Closely and It Checks Out
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
M&A Appetite in Pharma Has Proved Potent: Chart of the Day
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
A Pair of Rare Disease Biotech Concerns Worth a Good Look
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon
Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.
Real Money Post-Industrial Average Leads Major Indexes So Far for Year
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
